About Glycomantra
Glycomantra is a company based in Washington (United States) founded in 2014. Glycomantra offers products and services including Galectin-3 Inhibitors, NASH Therapeutics, and Type 2 Diabetes Drugs. Glycomantra operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Washington, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$3.7 M (USD), Grant
Dec 11, 2023
-
Investors
NIH
& 2 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Glycomantra
Glycomantra offers a comprehensive portfolio of products and services, including Galectin-3 Inhibitors, NASH Therapeutics, and Type 2 Diabetes Drugs.
Targets galectin-3 for cancer progression and metastasis inhibition
Addresses liver fibrosis in NASH through carbohydrate-based drugs
Develops treatments for diabetes via abnormal interaction countermeasures
Funding Insights of Glycomantra
Investors in Glycomantra
Glycomantra has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, TEDCO and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund and startup accelerator programs focused on seed and early stage companies
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked | |
|
Administers health care and support for military personnel and operations.
|
Locked | Locked | Locked |
Investor details for Glycomantra
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Glycomantra
Investment portfolio details for Glycomantra
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Glycomantra
Detailed financials for Glycomantra
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Glycomantra Comparisons
Peer comparison for Glycomantra
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Glycomantra
Glycomantra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Glycomantra
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Glycomantra
Complete news archive for Glycomantra
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Glycomantra
Glycomantra was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Glycomantra is headquartered in Washington, United States. It is registered at Washington, District Of Columbia, United States.
Founded in 2014, Glycomantra operates in the biotechnology sector with a focus on translational glycobiology. Research efforts center on discovering carbohydrate inhibitors for galectin-3, a protein linked to cancer and fibrotic diseases through immune system modulation. Molecules with picomolar affinity to galectin-3 have been identified using the companys platform. Services for protein purification and assay development are also provided.
Glycomantra's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Glycomantra offers Galectin-3 Inhibitors, NASH Therapeutics, and Type 2 Diabetes Drugs.
Glycomantra has 3 investors. Key investors include NIH, TEDCO, and Military Health.